• Home  /
  • Healthcare   /
  • Stock Movements Activity: Anthera Pharmaceuticals, Inc.’s (ANTH)

Stock Movements Activity: Anthera Pharmaceuticals, Inc.’s (ANTH)

Anthera Pharmaceuticals, Inc.’s (ANTH) , a stock from Biotechnology Industry, has a value of $0.71 per share, noted a price change of 11.79% in recent trade close. The price to sales ratio is 13.25. The lower price P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. A low P/S ratio may indicate possible undervaluation, while a ratio that is significantly above the average may suggest overvaluation. Abbreviated as the P/S ratio or PSR, this ratio is also known as a “sales multiple” or “revenue multiple.”

Annual earnings per share (EPS) growth noted at 41.20% in past 5 Years The company is estimating to achieve earnings per share (EPS) growth of 27.30% in this year and the earnings per share (EPS) growth expected to be 18.90% in the next year.

The stock has P/B of 3.95. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock’s market value to its book value. It is calculated by dividing the current closing price of the stock by the latest quarter’s book value per share. A lower P/B ratio could mean that the stock is undervalued. However, it could also mean that something is fundamentally wrong with the company. As with most ratios, be aware that this varies by industry. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately.

Analysts mean Recommendation on a stock is noted at 2.60. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.

The performance for week is 25.17% and the performance for quarter is at -63.53%. The performance for month is 7.74% and the performance for half year is -79.20%. Its monthly volatility value of 9.53% and volatility for the week is valued at 9.87%. The performance for Year to Date (YTD) is 9.57%.

51.30% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of -0.29% in last three month period. Insiders own 12.46% of Anthera Pharmaceuticals, Inc.’s (ANTH) shares. During last six month record, the net percent change kept by insiders has observed a change of 0.00%.

Indicating how profitable this stock is relative to its assets, the ROA value is observed at -154.20%. The ROA tells us exactly what earnings were generated from the invested capital. A ROI of -88.80% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.

P/E Ratio is for valuing a company that measures its current share price relative to its per-share earnings. The price to earnings ratio indicates the expected price of a share based on its earnings. As a company’s earnings per share being to rise, so does their market value per share. A company with a high P/E ratio usually indicated positive future performance and investors are willing to pay more for this company’s shares. A company with a lower ratio, on the other hand, is usually an indication of poor current and future performance. This could prove to be a poor investment. Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company’s Phase III product candidates include liprotamase or Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, and others.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a comment